COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.


Update as of  Feb. 26, 2021

XIFIN analyzed its vast stores of data, representative of four out of five top integrated delivery networks (IDNs) and seven out of the top ten independent laboratories nationwide, to craft the Lab Volume Index.

Currently, XIFIN sees 20-25% of all COVID-19 testing claims nationwide. The Lab Volume Index synthesizes billing volume data into a measurement of testing volumes as compared to a pre-coronavirus testing average (“baseline”).

Baseline volume is an average of weekly volumes represents current year pre-COVID-19 testing volumes. The Lab Volume Index measures billing volume data against a baseline volume, expressed as a percent of baseline.

This past week, overall testing volumes fell sharply, landing at 161% of baseline, 32 percentage points below the prior week. Routine and COVID-19 testing decreases equally contributed to the decline. The Presidents’ Day holiday and severe winter storms certainly contributed to reduced amounts, though we will need to see what happens in coming weeks to know how much could be part of an ongoing trend in decreased COVID-19 testing demand. Routine testing dipped to 84% of prepandemic volumes. COVID-19 testing stands at October 2020 levels, at 75% of baseline. Antibody testing also decreased, and now stands at 2% of baseline.

Volumes were down across all segments this week, though only one — Pathology — has fallen below prepandemic levels. Here is a segment-by-segment breakdown:

  • The Molecular segment saw the steepest drop this week, down 98% to land at 275% of baseline. COVID-19 testing for the segment was down 68% to finish at 191% of baseline, but routine testing also fell 29% to land at 84% of baseline.
  • Pain/tox labs also saw significant decreases this week, down 38% in total to land at 185% of baseline. COVID-19 decline outstripped routine testing declines over two to one, with COVID-19 testing down 26% and routine down 12%.
  • Hospital labs finished the week at 141% of volume. While COVID-19 testing was down only 5%, routine testing fell 25%.
  • ​​​​​​​Clinical labs had the smallest drop for the week, down 18% overall to land at 165% of baseline.
  • Pathology volumes decreased 28% overall. The segment ended the week just shy of baseline at 99%, the first to drop below 100% since June.